Insight Molecular Diagnostics Inc. Ordinary Shares IMDX 深 滬
等待開盤 08-14 09:30:00 美东时间
2.45
-0.060
-2.39%
華盛通- 最 高2.59
- 今 開2.57
- 成交量 1.59万股
- 最 低 2.45
- 昨 收 2.51
- 總市值 7006.83万
- 52周最高 4.75
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 1.922
- 委 比 71.17%
- 總股本 2859.93万
- 歷史最高 204.80
- 量 比 0.59
- 振 幅 5.58%
- 歷史最低 1.922
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OncoCyte GAAP EPS of -$0.30
OncoCyte press release (NASDAQ:IMDX): Q2 GAAP EPS of -$0.30. The company’s cash, cash equivalents, and restricted cash balance at the end of the second quarter was $26.0 million. More on OncoCyte On...
08-12 04:49
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Exploring Insight Molecular's Earnings Expectations
Insight Molecular (NASDAQ:IMDX) is set to give its latest quarterly earnings re...
08-09 04:04
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
Insight Molecular Diagnostics (iMDx) announced the release of its Q2 2025 financial results after market close on August 11, 2025, with a live Zoom webinar to discuss the results at 2:00 PM PT / 5:00 PM ET. Registration for the webinar is available at the provided link, and an archived replay will be accessible on iMDx’s investor relations website post-event. Additionally, on August 12, 2025, CEO Josh Riggs and CFO Andrea James will attend the 10...
08-04 20:05
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients
iMDx announced a novel dd-cfDNA detection method combining relative and absolute measurements, significantly improving positive predictive value for transplant rejection, reducing false positives and unnecessary biopsies. The method will be presented at the World Transplant Congress and further evaluated in an FDA study. With enhanced clinical utility, it holds promise for improving patient care.
07-30 20:05
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025
Insight Molecular Diagnostics (iMDx) will host a virtual KOL event on August 15, 2025, featuring Anthony Langone, MD, discussing donor-derived cell-free DNA (dd-cfDNA) in transplant care. iMDx's GraftAssure™ products leverage advanced dPCR technology for reliable dd-cfDNA results, with plans for an in-house clinical test kit. The event will also cover the company's kitted strategy and recent rebranding, including relocation to Nashville. Visit <h...
07-28 20:05
InspireMD to Announce Second Quarter 2025 Financial Results
<p>MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc., developer of the CGuard® Prime carotid stent system for stroke prevention, will release its second quarter 2025 financial results on August 5, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties can access the call via telephone or webcast. A replay will be available on Inspi...
07-22 11:00
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
<p>Inspeq News</p> <p>Inspeq has launched the CGuard Prime carotid stent system in the U.S. following FDA approval. The system features a dual-layer design, MicroNet mesh, and SmartFit technology to minimize embolism risk. With double-digit market share in over 30 countries, the company aims to expand its presence in the U.S. using a seasoned commercial team. Experts laud the device for its advanced embolic protection and ease of use, offering ...
07-09 11:00
iMDx Reports Results From Study Evaluating Flagship Test Kit Technology In Head-to-head Comparison With Another Commercially Available Test Kit.
Study indicates iMDx flagship technology's equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx's digital PCR-based test kits with NGS kits shows consistent results in 96 transplant
06-24 04:06
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
Insight Molecular Diagnostics (iMDx) announced positive results from a study comparing its digital PCR-based test kit (GraftAssureIQ) with next-generation sequencing (NGS) kits for detecting donor-derived cell-free DNA (dd-cfDNA). The study, involving 96 kidney transplant patients, showed equivalent results in measuring dd-cfDNA levels, a key biomarker for transplant rejection. iMDx's technology demonstrated improved analytical sensitivity, parti...
06-23 20:05
